Empty Shelves, Unanswered Questions: Understanding Why Azithromycin Disappears From US Pharmacies

For most Americans, picking up a prescription antibiotic is a routine errand. You visit your physician, receive a diagnosis, and stop at the pharmacy on the way home. That assumption of seamless availability, however, has been disrupted with increasing frequency when it comes to azithromycin — a macrolide antibiotic prescribed for everything from community-acquired pneumonia to sexually transmitted infections. In recent years, patients across the country have encountered backorders, partial fills, and outright unavailability at both independent pharmacies and major retail chains.

Understanding why this happens — and what it means for you as a patient — requires looking well beyond the pharmacy counter.

The Anatomy of a Drug Shortage

Drug shortages in the United States rarely have a single cause. Instead, they tend to emerge from the intersection of several systemic vulnerabilities operating simultaneously.

Azithromycin is a generic medication, which means its profit margins are comparatively thin. Manufacturers operating in a low-margin environment have little financial incentive to maintain substantial excess production capacity. When demand spikes unexpectedly — whether due to a respiratory illness season, a public health emergency, or a surge in prescribing — the existing supply chain lacks the buffer needed to absorb the shock.

Compounding this is the geographic concentration of active pharmaceutical ingredient (API) manufacturing. A significant proportion of the raw chemical compounds used to produce azithromycin are synthesized in facilities located in India and China. When those facilities face regulatory action, natural disasters, labor disruptions, or export restrictions, the downstream effects ripple through to American pharmacy shelves within weeks. The U.S. Food and Drug Administration (FDA) has long flagged this dependence on foreign API sources as a structural vulnerability in the national drug supply.

Demand Surges and the Role of Public Health Emergencies

The COVID-19 pandemic provided a stark illustration of how rapidly demand can outpace supply. Early in the pandemic, azithromycin was promoted in certain circles — including on social media platforms — as a potential treatment for the virus. Despite the absence of clinical evidence supporting this use, prescribing rates climbed sharply in 2020. Pharmacies that had maintained adequate stock for typical bacterial infection caseloads suddenly faced requests that bore no relationship to normal demand patterns.

Even without a global pandemic, respiratory illness seasons create predictable demand spikes. During periods when strep throat, walking pneumonia, and sinusitis cases surge — particularly in the fall and winter months — azithromycin prescriptions climb correspondingly. If manufacturers have not anticipated the volume, shortages follow.

The FDA maintains a publicly accessible drug shortage database, and azithromycin has appeared on that list during multiple distinct periods. Each listing represents real patients who were unable to fill prescriptions as written.

What Patients Experience at the Pharmacy Level

The practical experience of an azithromycin shortage varies depending on location, pharmacy size, and the specific formulation prescribed. Oral tablets in the standard Z-Pack configuration (six 250 mg tablets) may be unavailable while the 500 mg single-tablet formulation remains in stock — or vice versa. Liquid suspensions formulated for pediatric patients are often among the first presentations to face shortages, given their narrower manufacturing base and the fact that children are frequent recipients of azithromycin prescriptions for ear infections and strep.

Patients may be offered a partial fill — enough medication to begin treatment, with the remainder promised when new stock arrives. Others may be advised to contact additional pharmacies in their area. In either case, the burden of navigating the shortage falls disproportionately on the patient, at a time when they are already managing an active illness.

How Prescribers Are Responding

Clinicians who encounter azithromycin shortages have several evidence-based alternatives to consider, depending on the underlying condition being treated.

For community-acquired pneumonia in otherwise healthy outpatients, doxycycline is frequently substituted and carries comparable clinical efficacy for many causative organisms. For streptococcal pharyngitis, amoxicillin and penicillin V remain first-line choices and are generally not affected by the same supply constraints as azithromycin. For certain sexually transmitted infections such as chlamydia, doxycycline has re-emerged as the preferred treatment in updated CDC guidelines, partly as a response to azithromycin resistance concerns and partly because it remains more consistently available.

Patients who have been prescribed azithromycin and cannot obtain it should contact their prescribing physician's office promptly rather than waiting indefinitely for stock to materialize. A brief telehealth consultation or a message through a patient portal may be sufficient to arrange an alternative prescription without an additional in-person visit.

The Policy Landscape: What Is Being Done

Federal and state policymakers have grown increasingly attentive to the drug shortage problem, though meaningful structural reform has proven elusive. The FDA has expanded its shortage prevention authorities under various legislative updates and works with manufacturers to anticipate supply disruptions before they reach critical levels. The agency also has the ability to expedite review of manufacturing site changes or alternative suppliers when shortages are declared.

Beyond regulatory action, there has been growing bipartisan interest in incentivizing domestic API manufacturing as a national security and public health priority. The Rosemount Act and similar legislative proposals have sought to create financial incentives for pharmaceutical manufacturers to establish or expand production within the United States, reducing dependence on overseas suppliers for essential medications.

Some healthcare systems and hospital networks have begun maintaining strategic reserves of critical generic medications, including certain antibiotics, to buffer against short-term supply disruptions. However, this approach is not uniformly implemented across the country, and patients receiving care through smaller practices or independent providers may not benefit from such arrangements.

Practical Guidance for Patients Facing a Shortage

If you present a valid azithromycin prescription at your pharmacy and are told the medication is unavailable, consider the following steps:

• Ask about alternative formulations. If the standard Z-Pack is out of stock, a different dosage presentation of the same drug may be available.
• Call ahead to other pharmacies. Most pharmacies can confirm stock availability by phone, sparing you an unnecessary trip.
• Contact your prescriber immediately. Do not delay treatment while waiting for stock to arrive. Your physician can evaluate whether an alternative antibiotic is clinically appropriate for your specific diagnosis.
• Check the FDA shortage database. The agency's publicly available resource at accessdata.fda.gov can confirm whether an official shortage has been declared and may provide additional context.
• Avoid stockpiling. Purchasing more azithromycin than your current prescription requires — when it is available — contributes to the very shortage conditions that create these access problems.

Looking Ahead

Azithromycin shortages are not an anomaly. They are a predictable consequence of a generic drug market that prioritizes cost efficiency over supply resilience, combined with a manufacturing infrastructure that remains heavily dependent on a small number of overseas facilities. Until systemic reforms address these underlying vulnerabilities, patients and providers alike will need to remain adaptable.

At ZithromaxAll, we believe that informed patients are better positioned to navigate disruptions in medication access. Knowing what to ask, whom to call, and what alternatives exist can make the difference between a treatment delay and a timely recovery. The antibiotic supply chain is complex — but your response to a shortage does not have to be.